12 September 2023
12 September 2023
Lord James O’Shaughnessy talks to the Clinical Trials Arena team about his review of commercial clinical trials in the UK and the path the country can take to recovery.
The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with eosinophilic granulomatosis with polyangiitis.
Merck presented new post-hoc and long-term data analyses further showing sotatercept’s safety and efficacy in PAH.
The agreement allows Sandoz exclusive marketing rights for the inflammatory bowel disease therapy in Europe and North America.
Regeneron is developing an antibody for Covid-19 prevention with the help of US government funding.
The overall response rate was 100% one month after treatment.
The initial primary endpoint data is anticipated later this year or in the early first quarter of next year.
Change from baseline in the distance walked on the six-minute test is the primary efficacy outcome of the study.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. KOLs remain hopeful that these companies will uncover a class of drugs that works effectively to slow or modify the disease course. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs.
Give your business an edge with our leading industry insights.
